Deep Medicine Acquisition Corp. (DMAQ) Stock

About Deep Medicine Acquisition Corp.

Deep Medicine Acquisition Corp. (DMAQ) currently operates as a non-operating entity, possessing no substantial business functions of its own. Its express purpose is to execute a business combination, which could entail a merger, an acquisition of equity or assets, or a reorganization, with one or more target companies. The firm's strategic efforts are specifically concentrated on identifying promising enterprises within the healthcare industry. Incorporated in 2020, DMAQ maintains its principal place of business in New York, New York.

Deep Medicine Acquisition Corp. is headquartered in US.

Deep Medicine Acquisition Corp. (DMAQ) stock trades at $2.96 with a market capitalization of $12.90M. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.20, price-to-sales of 0.68. Over the past 52 weeks the stock has ranged between $2.96 and $19.91, and currently trades 85.1% below its 52-week high.

On profitability, Deep Medicine Acquisition Corp. generates a return on equity (ROE) of -317.72%, return on capital employed of -105.59%, an operating margin of -32.32%, a net profit margin of -80.66%.